Abstracts Archive - Page 2409 of 2425 - ACR Meeting Abstracts

Abstract Number: 206 • 2012 ACR/ARHP Annual Meeting
Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health
Lisa G. Rider¹, Adrienne L. Yip², Iren Horkayne-Szakaly³, Rita Volochayev², Joseph A. Shrader⁴, Maria L. Turner⁵, Heidi H. Kong⁵, Minal S. Jain⁴, Anna V. Jansen¹, Chester V. Oddis⁶, Thomas A. Fleisher⁷ and Frederick W. Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Joint Pathology Center, Silver Spring, MD, ⁴Rehabilitation Medicine, Rehab Medicine, NIH Clinical Center, Bethesda, MD, ⁵Dermatology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Laboratory Medicine, Laboratory Medicine, NIH Clinical Center, Bethesda, MD
Background/Purpose: To assess changes in myositis core set measures, clinical and laboratory data, and paired muscle biopsies from NIH patients enrolled in the Rituximab in…
Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Maria Manara¹, Carlo Alberto Scirè¹, Marco A. Cimmino², Marcello Govoni³, Fausto Salaffi⁴, Greta Carrara¹, Carlomaurizio Montecucco⁵, Marco Matucci-Cerinic⁶, Giovanni Minisola⁷ and Kick-off of the Italina Network for Gout (KING) Study Group⁸, ¹Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ²Rheumatology - Department of Internal Medicine - University of Genoa, Genova, Italy, ³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ⁴Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, ⁵Division of Rheumatology - University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁶Department of Biomedicine & Division of Rheumatology AOUC - University of Florence, Florence, Italy, ⁷Rheumatology Unit - San Camillo Forlanini Hospital, Rome, Italy, ⁸Italian Society for Rheumatology, SIR, Italy
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…
Abstract Number: 168 • 2012 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction
Lamiae Grimaldi-Bensouda¹, Annick Alpérovitch², Elodie Aubrun¹, Nicolas Danchin³, Michel Rossignol⁴, Lucien Abenhaim⁵, Pascal Richette⁶ and PGRx MI Group⁷, ¹LA-SER, Paris, France, ²Inserm U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, Paris, France, ³Coronary disease unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris and Paris-Descartes University, Paris, France, ⁴LA-SER, Centre for Risk Research, Montreal, Canada, ⁵LA-SER Europe Ltd, London, United Kingdom, ⁶Lariboisière Hospital, Paris, France, ⁷Paris, France
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects…
Abstract Number: 169 • 2012 ACR/ARHP Annual Meeting
Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout
Kenneth M. Bahrt¹, Anthony E. Yeo², Tina L. Howson³ and Faith D. Ottery¹, ¹Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ²Savient Pharmaceuticals, Inc., East Brunswick, NJ, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG which was approved in the US in 2010 for treating hyperuricemia in patients with…
Abstract Number: 170 • 2012 ACR/ARHP Annual Meeting
Relative Risk of Infusion Reactions with KRYSTEXXA® (pegloticase) From Post-Approval Safety Data: Results From Sept 2010 to June 2012
Raymond L. Malamet¹, Tina L. Howson², Anthony E. Yeo³, Kenneth M. Bahrt⁴ and Marsha Wolfson³, ¹Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ²Savient Pharmaceuticals, Inc., Bridgewater, NJ, ³Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁴Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: During randomized clinical trials (RCTs) with pegloticase, the incidence of infusion-related reactions (IRs) was 26% including 5 cases of anaphylaxis (determined post-hoc using published…
Abstract Number: 171 • 2012 ACR/ARHP Annual Meeting
Disease Modifying Agents Combined with Isoniazid for Latent Tuberculosis in Patients with Rheumatic Diseases
Josiane Bourré-Tessier¹, Mireia Ariño i Torregrosa² and Denis Choquette³, ¹Médecine, Institut de Rhumatologie de Montréal, Université de Montréal, Montréal, QC, Canada, ²Universitat de Valencia, Massanassa, Spain, ³Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
Background/Purpose: Reactivation of latent tuberculosis (LTB) has been described with the use of anti-TNF for the treatment of rheumatic diseases. Combined treatment of isoniazid (INH)…
Abstract Number: 172 • 2012 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Antibiotic Treatment for Reactive Arthritis
Claire E. Barber¹, Joseph Kim², Robert D. Inman³, John Esdaile⁴ and Matthew T. James⁵, ¹Rheumatology, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, Canada, ³Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Medicine, Univeristy of Calgary, Calgary, Canada
Background/Purpose: Although bacterial infections are a common precipitant, it is unclear whether antibiotic treatment is effective for reactive arthritis. The purpose of this study was…
Abstract Number: 173 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work?
Ieda Laurindo¹, Ana C. M. Ribeiro¹, Julio C. B. Moraes², Carla G.S. Saad¹, Karina Rossi Bonfiglioli³, Fernando H.C. Souza³, Ana L. G. Calich¹, Mariana G. Waisberg¹, Lissiane K. N. Guedes³ and Eloisa Bonfa¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Background: Current recommendations for latent tuberculosis infection (LTB) screening and treatment in patients eligible for anti-TNF agents are not well established in endemic regions.…
Abstract Number: 174 • 2012 ACR/ARHP Annual Meeting
Prevalence, Risk Factors, and Functional Impact of Arthralgias Among Patients with Chronic Hepatitis C Virus Infection
Samir Bhangle¹, Vincent Lo Re², W. Gina Pang¹, Kyong-Mi Chang³, Valerianna Amorosa⁴, Jay Kostman⁵, H. Ralph Schumacher⁶ and Alexis Ogdie⁷, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Dept of Medicine/Infection Diseases, Dept of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Gastroenterology, Philadelphia VA Medical Center, Philadelphia, PA, ⁴Division of Infectious Diseases, Philadelphia VA Medical Center, Philadelphia, PA, ⁵Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA, ⁶Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁷Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The prevalence, risk factors and functional impact of joint pain are not well described in chronic hepatitis C virus (HCV)-infected patients, particularly in the…
Abstract Number: 175 • 2012 ACR/ARHP Annual Meeting
The Impact of Hepatitis Screening On Diagnosis and Treatment in Rheumatoid Arthritis
Richard Conway¹, Michele Doran², Finbar (Barry) D. O'Shea³ and Gaye Cunnane², ¹Rheumatology, St James's Hospital, Dublin, Ireland, ²Dept of Rheumatology, St James's Hospital, Dublin, Ireland, ³Rheumatology Dept, St James's Hospital, Dublin, Ireland
Background/Purpose: Hepatitis testing is an important pre-requisite to the diagnosis and treatment of patients with rheumatic disease. Joint symptoms may be a manifestation of acute…
Abstract Number: 176 • 2012 ACR/ARHP Annual Meeting
Prevalence and Associations of Hepatitis C Arthritis in Chronic Hepatitis C Virus Infection
Elizabeth D. Ferucci¹, Holly S. Ryan², Tammy L. Choromanski¹, Lisa J. Townshend-Bulson², Stephen E. Livingston², Brian J. McMahon² and Mark H. Wener³, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Alaska Native Tribal Health Consortium, Anchorage, AK, ³Rheumatology & Lab Med, University of Washington, Seattle, WA
Background/Purpose: Chronic infection with hepatitis C virus (HCV) has been reported to cause inflammatory arthritis and/or fibromyalgia. Case series of patients with HCV-associated arthritis have…
Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Peptides in Tuberculosis
Isabella Lima¹, Rodrigo Oliveira², Ajax Atta², Samyra Marchi³, Lúcio Barbosa³, Eliana Reis³, Mitermayer G. Reis³ and Mittermayer Santiago⁴, ¹Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, ²Universidade Federal da Bahia, Salvador, Brazil, ³Fundação Oswaldo Cruz, Salvador, Brazil, ⁴Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…
Abstract Number: 178 • 2012 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin in Parvovirus B19 Mediated Pure Red Cell Aplasia: A Retrospective Study in 10 Patients and a Review of 123 Cases
Yoann Crabol, Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: The efficacy of intravenous immunoglobulin (IVIg) therapy in patients with pure red cell aplasia (PRCA) related to human parvovirus B19 (HPV-B19) infection is mainly…
Abstract Number: 179 • 2012 ACR/ARHP Annual Meeting
Evaluation of Anakinra Therapy in Seven Adults After Suboptimal Response to Etanercept Therapy for Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome
Amanda K. Ombrello¹, Patrycja M. Hoffmann¹, Anne Jones¹, Karyl Barron² and Daniel L. Kastner¹, ¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Div Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
Background/Purpose: Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome (TRAPS) is an autoinflammatory disease inherited in an autosomal dominant fashion. TRAPS develops secondary to mutations in…
Abstract Number: 180 • 2012 ACR/ARHP Annual Meeting
Safety of Canakinumab in a Large Cohort of Patients with Cryopyrin-Associated Periodic Syndrome: Results From the ß-Confident Registry
H. Hoffman¹, J. B. Kuemmerle-Deschner², P. Hawkins³, T. van der Poll⁴, Ulrich A. Walker⁵, B. Rauer⁶, J. M. Nebesky⁶ and H. Tilson⁷, ¹University of California at San Diego, San Diego, CA, ²Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ³University College London Medical School, London, United Kingdom, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology, Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷The University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is an extremely rare autoinflammatory disorder associated with overproduction of interleukin-1β (IL-1β). Canakinumab, a fully human, selective, anti-IL-1β monoclonal antibody,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].